Adenine-induced chronic kidney and cardiovascular damage in rats

被引:106
作者
Diwan, Vishal [1 ,3 ]
Mistry, Anand [2 ]
Gobe, Glenda [3 ]
Brown, Lindsay [2 ]
机构
[1] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
[2] Univ So Queensland, Dept Biol & Phys Sci, Toowoomba, Qld 4350, Australia
[3] Univ Queensland, Sch Med, Ctr Kidney Dis Res, Brisbane, Qld 4072, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Adenine; Chronic kidney disease; Cardiovascular disease; Allopurinol; Uric acid; Rats; CHRONIC-RENAL-FAILURE; LEFT-VENTRICULAR MASS; PHOSPHOLIPASE A(2); URIC-ACID; DISEASE; ALLOPURINOL; PROTEINURIA; PROGRESSION; INJURY; INFLAMMATION;
D O I
10.1016/j.vascn.2013.05.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The incidence of human chronic kidney failure with associated cardiovascular disease is increasing. Kidney damage can be induced in rats by chronic dietary adenine intake. We have used this intervention to investigate the development of concurrent kidney and cardiovascular injury. Methods: Dose-ranging studies were undertaken on male Wistar rats by feeding with adenine (0.075%, 0.25%, 0.5% or 0.75%) for up to 16 weeks. 0.075% adenine produced minimal changes while 0.5% or 0.75% adenine produced marked kidney damage; 0.25% adenine was chosen for further studies since it produced moderate kidney and cardiovascular damage. In rats fed 0.25% adenine, renal function (blood urea nitrogen (BUN), plasma creatinine, and their clearances; plasma uric acid; proteinuria); renal structure (collagen, apoptosis, inflammation, glomerulopathy); and protein expression of markers for oxidative stress (HO-1), fibrosis (TGF-beta, alpha-SMA) and inflammation (TNF-alpha, NF-kappa B p52, NF-kappa B p50, PLA(2) and ED1) were measured, along with cardiovascular parameters (blood pressure, left ventricular stiffness, vascular responses). Allopurinol (25 mg/kg/day, final 8 weeks only) was administered to determine the role of uric acid. Results: 0.25% adenine diet induced characteristics of human chronic kidney disease at 16 weeks including increased BUN (0.25% adenine 56.5 +/- 5.4*; control 6.2 +/- 0.6 mmol/L; * = p < 0.05) and plasma creatinine (0.25% adenine 268 +/- 23*; control 41.9 +/- 2.8 mu g/L), decreased BUN and creatinine clearances; proteinuria; increased chronic inflammation as macrophage and myofibroblast infiltration, increased collagen deposition, tubular atrophy, apoptosis, and TNF-alpha and TGF-beta expression; glomerulopathy as increased podocyte desmin expression; increased HO-1 expression; and increased plasma uric acid. Cardiovascular changes included increased ventricular fibrosis, systolic blood pressure and left ventricular stiffness, and impaired vascular responses. Allopurinol decreased plasma uric acid concentrations and reversed the adenine-induced kidney and cardiovascular changes. Conclusion: Administration of 0.25% adenine to rats induced chronic kidney and cardiovascular disease. Increased uric acid production is the most likely cause since allopurinol attenuated this damage. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:197 / 207
页数:11
相关论文
共 42 条
[1]   Protective effects of allopurinol against acute liver damage and cirrhosis induced by carbon tetrachloride: Modulation of NF-κB, cytokine production and oxidative stress [J].
Aldaba-Muruato, Liseth R. ;
Moreno, Mario G. ;
Shibayama, Mineko ;
Tsutsumi, Victor ;
Muriel, Pablo .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2012, 1820 (02) :65-75
[2]   New model for adenine-induced chronic renal failure in mice, and the effect of gum acacia treatment thereon: Comparison with rats [J].
Ali, Badreldin H. ;
Al-Salam, Suhail ;
Al Za'abi, Mohammed ;
Waly, Mostafa I. ;
Ramkumar, Aishwarya ;
Beegam, Sumyia ;
Al-Lawati, Intisar ;
Adham, Sirin A. ;
Nemmar, Abderrahim .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 68 (03) :384-393
[3]   Use of genetic mouse models in the study of diabetic nephropathy [J].
Allen T.J. ;
Cooper M.E. ;
Lan H.Y. .
Current Diabetes Reports, 2004, 4 (6) :435-440
[4]  
Anders HJ, 2000, EXP NEPHROL, V8, P181
[5]  
Australian Institute of Health and Welfare, 2009, OV CHRON KIDN DIS AU
[6]   Uric acid: a novel mediator and marker of risk in chronic kidney disease? [J].
Feig, Daniel I. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (06) :526-530
[7]   Mechanisms of progression of chronic kidney disease [J].
Fogo, Agnes B. .
PEDIATRIC NEPHROLOGY, 2007, 22 (12) :2011-2022
[8]   INDUCTION OF CHRONIC RENAL-FAILURE IN THE MOUSE - A NEW MODEL [J].
GABIZON, D ;
GOREN, E ;
SHAKED, U ;
AVERBUKH, Z ;
ROSENMANN, E ;
MODAI, D .
NEPHRON, 1985, 40 (03) :349-352
[9]  
Gobe Glenda, 2009, V466, P175, DOI 10.1007/978-1-59745-352-3_13
[10]   Risk Factors for End-Stage Renal Disease 25-Year Follow-up [J].
Hsu, Chi-yuan ;
Iribarren, Carlos ;
McCulloch, Charles E. ;
Darbinian, Jeanne ;
Go, Alan S. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (04) :342-350